RxDoctor Payments DataLook up a doctor →

Grace Shumaker, MD

Hematology & Oncology · Jackson, MSNPI 1912901513

Payments from drug & device makers

$9,914in general payments, 2019–2025

Across 345 payments — averaging $28.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$3K
  • Puma Biotechnology, Inc.$633
  • Bristol Myers Squibb$516
  • Incyte Corporation$437
  • Gilead$391
  • AstraZeneca$358
  • plus $5K from 54 others

What the payments were for

  • Food & beverage$6,63997%
  • Education$2313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,914 in reported general payments places this provider in the 40th percentile of 57 hematology & oncology providers in Mississippi.

See all hematology & oncology providers in Mississippi

Medicare billing

Part B allowed, 2024
$48,773
Medicare patients
213
Services billed
592

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib15$229,810
ImbruvicaIbrutinib11$180,742
XareltoRivaroxaban26$15,473
Exemestane40$7,902
EliquisApixaban12$7,590
Letrozole145$2,880
Tamoxifen Citrate85$1,616
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$652
Potassium Chloride15$627
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$436
Gabapentin49$390
Anastrozole18$375
Albuterol Sulfate HfaAlbuterol Sulfate12$359
Acyclovir25$201
Levofloxacin11$193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$202$237,40027 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$112$180,74211 claims
Johnson & JohnsonXarelto$277$15,47326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 57 hematology & oncology providers in Mississippi.

Other hematology & oncology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →